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DEVELOPMENT OF NOVEL SHIVS FROM HIV-1 CLADES FOR 
PRECLINICAL EVALUATION 
KEVIN CLYDE GASMEÑA PASTORES 
ABSTRACT 
The lack of an animal model that recapitulates the prominent features of 
HIV-1 infection in humans limits the search for preventative and curative 
strategies against HIV-1. As stated by the National Institutes of Health (NIH), 
developing highly pathogenic simian-human immunodeficiency viruses (SHIVs) 
that can establish persistent infections and AIDS progression in rhesus 
macaques (RMs) remains vital for advancing the field.  
 The HIV-1 envelope (Env) serves as a major target in vaccine studies. 
SHIVs - which are chimeras of the simian immunodeficiency virus (SIV) 
backbone and a humanized Env, are utilized for preclinical evaluation of vaccines 
and therapeutics aimed at targeting the Env glycoprotein. However, SHIVs 
presently available poorly infect RM due to weak binding interactions between 
Env and rhesus CD4 (rhCD4).  
Position 375 (Env375) lies within the rhCD4 binding pocket of HIV-1 Env. 
Accordingly, substituting the wild-type (WT) amino acid in Env375 for bulky 
hydrophobic and/or basic amino acids may strengthen Env-rhCD4 interactions. 
These mutations should increase the pathogenicity of our original SHIV 
challenge stocks (SHIV162p3 and SHIVAE16) and allow for the development of 
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an animal model that closely mirrors HIV-1 acquisition and chronic AIDS infection 
in humans.  
 
OBJECTIVES 
 To develop an animal model that recapitulates HIV-1 infection and AIDS 
progression in humans. 
 
MATERIALS AND METHODS 
 SHIV design involved insertion of human env sequences into a modified 
SIV backbone (provided by Dr. George Shaw, University of Pennsylvania). Site-
directed mutagenesis was employed to introduce amino acid substitutions at 
Env375 for the following residues: serine, histidine, methionine, tryptophan, 
tyrosine, and phenylalanine. These constructs were then utilized for transfection 
of human embryonic kidney cells (293T) with viral supernatants collected 72 
hours post-transfection. 293T viral supernatants were then used to infect human 
and rhesus PBMCs with the resulting supernatant harvested every three days 
and subjected to ELISA to monitor viral growth. Viruses were further 
characterized by RT-PCR for quantification and TCID50 assays to determine 
infectious dose. Resulting SHIVs were then used for challenge studies in rhesus 
macaques. 
 Sixteen rhesus macaques were divided into groups of four that received 
the following SHIV challenge stocks: (1) original SHIV162p3, (2) modified 
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SHIV162p3, (3) original SHIVAE16, and (4) modified SHIVAE16. Following 
infection, animal plasma and sera were collected and subjected to post-challenge 
analyses such as cellular assays and measurements of plasma viral RNA levels.  
  
RESULTS 
 Several analyses were conducted to study the pathogenicity of the 
modified SHIV162p3 and SHIVAE16 relative to the original stocks. Regarding 
SHIV infectivity, several versions of the modified SHIVs exhibited greater in vitro 
infectivity titers than the original stocks. Additionally, preliminary viral load 
analyses conducted in vivo indicate that all sixteen RMs challenged with original 
and modified SHIVs were infected at comparable levels. Furthermore, CD4+ T 
cell counts were measured and all sixteen animals exhibited declines in CD4+ T 
cell percentages. 
 
CONCLUSION 
 In sum, the modified SHIVs may improve animal models by closely 
recapitulating the events of HIV-1 infection in humans and serve better for future 
studies of preventative and curative treatments against HIV-1. 
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INTRODUCTION 
 
 Human Immunodeficiency Virus Type 1 (HIV-1) belongs to the lentivirus 
family of retroviruses. HIV-1 consists of two RNA strands and proteins 
encapsulated within a protein core that is surrounded by a lipid envelope. The 
lipid envelope is derived from the host and has viral glycoproteins utilized for cell 
surface attachment and entry. The RNA strands packaged within the protein core 
are approximately 9.2 kb long and encode gene products necessary for the viral 
life cycle (Abbas et al., 2016). As shown in Figure 1, the HIV-1 life cycle 
encompasses seven general stages: attachment, fusion, reverse transcription, 
integration, replication, assembly, and budding (aidsinfo.nih.gov, 2016).  
 During attachment, HIV-1 binds to the target cell using a viral protein 
called Env. HIV-1 Env is initially synthesized as a gp160 precursor and is 
subsequently cleaved into two subunits, gp120 and gp41. However, the 
functional Env exists as a trimer consisting of three pairs of gp120 and gp41 (Liu 
et al., 2017). In order for attachment to be successful, the Env trimer must bind to 
the target cell’s CD4 receptor. The Env-CD4 binding initializes a conformational 
change that allows the third variable loop (V3) of gp120 to form a secondary 
interaction with a coreceptor on the surface of the infected cell. Depending on the 
cell type, gp120 generally attaches to either the CXCR4 or CCR5 coreceptor. 
The binding of gp120 to either coreceptor induces a subsequent conformational 
change on gp41 that exposes the hydrophobic fusion peptide of the virus, which 
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facilitates the next stage of the HIV-1 life cycle: the fusion of the viral envelope to 
the host cell’s membrane (Wei et al., 2017). 
 Once HIV-1 is inside the cytoplasm, the proteases packaged within the 
protein core degrade the capsid to release RNA for transcription by the enzyme 
reverse transcriptase, which converts the viral genetic material into DNA 
(aidsinfo.nih.gov, 2016). Following reverse transcription, the viral DNA travels to 
the host cell’s nucleus for the next stage of the viral life cycle. Through the 
activity of the viral enzyme integrase, the viral DNA becomes integrated into the 
host cell’s genome, and at this stage, HIV-1 is classified as a provirus (Abbas et 
al., 2016).  
 By integrating its genetic material into the host genome, HIV-1 can evade 
the host’s immune response. Cytokine activation of the infected cell initiates the 
transcription of the host’s genome; consequently, this may lead to the 
transcription of the proviral DNA thereby inducing HIV-1 replication. During 
replication, HIV-1 utilizes the host machinery to produce the building blocks 
necessary for its propagation. The synthesis of viral particles leads to the 
assembly of new viruses ready to infect other cells. However, the virus remains 
immature until it buds from the infected cell and acquires a lipid envelope derived 
from the host cell’s membrane. (Abbas et al., 2016; aidsinfo.nih.gov, 2016). 
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Figure 1. HIV-1 Life Cycle. Propagation of HIV-1 requires successful entry, 
replication, and budding (https://aidsinfo.nih.gov/education-
materials/glossary/1596/life-cycle#). 
 
Pathogenesis 
HIV-1 transmission primarily occurs through the exchange of bodily fluids 
like semen or blood, either through direct sexual contact, or through 
percutaneous inoculation (Abbas et al., 2016). The subsequent pathogenesis 
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caused by HIV-1 infection can be divided into several stages: acute, chronic, and 
Acquired Immunodeficiency Syndrome (AIDS). 
 The infection of memory CD4+ T cells in the mucosal lymphoid tissues 
characterizes the acute stage of HIV-1 pathogenesis. The mucosal lining serves 
as one of the initial contact points for any pathogen attempting to compromise 
the host; thus, a high volume of mature T cells occupy the mucosal lining. During 
the course of HIV-1 pathogenesis, the infection leads to a drastic depletion of T 
cells that reside in the mucosal lining (Abbas et al., 2016). Acute infection begins 
with the eclipse phase, which is the period between the initial infection and when 
the virus becomes first detectable (McMichael et al., 2010). At this time, the virus 
remains clinically absent and continues to propagate and infect nearby cells. 
However, Descours et al. (2017) have shown through in vitro studies that a 
unique gene expression profile characterizes latently infected CD4+ T cells that 
harbor replication-competent proviruses; potentially, the presence of CD32a on 
CD4+ T cells may serve as a potential biomarker that may aid in early detection 
and treatments. Once the virus becomes detectable, the progression of HIV-1 
infection is classified in several Fiebig stages based on the presence or absence 
of different viral particles within the plasma (McMichael et al., 2010). The acute 
stage is critical because combating HIV-1 proves to be more successful with 
early detection. 
 Following the acute stage, an infected individual gradually transitions into 
the chronic stage, which is characterized by the dissemination of the virus, 
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viremia, and the development of immunological mechanisms to combat the virus. 
During viremia, an infected host exhibits high levels of virus. Additionally, the 
dissemination of virus allows for infection of other cells, such as dendritic cells 
and macrophages. Despite the manifestations of chronic infection, an infected 
individual develops an immune response through antigen recognition by 
functional CD4+ T cells and antigen-presenting cells (Abbas et al., 2016). 
 During the chronic phase of HIV-1 pathogenesis, the spleen and lymph 
nodes become the major sites of viral replication and T cell destruction. The 
immune system remains functional and responsive to most challenges during this 
phase; however, the destruction of T cells continues, this time primarily taking 
place in the lymphoid organs (Abbas et al., 2016).  
 A healthy individual typically has 500-1600 CD4+ T cells per cubic 
millimeter; but as evidenced by Figure 2, an infected individual falling below 200 
cells per cubic millimeter is considered to have AIDS (aidsinfo.nih.gov, 2016). 
HIV/AIDS was addressed to be a global epidemic in the 1980s. Presently, an 
approximated 35 million people around the world live with HIV/AIDS with 70% of 
infected individuals living in Africa, and 20% living in Asia. Unfortunately, an 
additional 3 million individuals around the world become diagnosed every year 
(aids.gov, 2016). 
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Figure 2. HIV-1 Progression, CD4+ T Cell Count, and Viral Loads. The solid 
line represents CD4+ T cell count. The dashed line represents copies of HIV-1 
RNA  in plasma. Below 200 cells per cubic millimeter, a person is diagnosed with 
AIDS. 
 
Host Immune Response to HIV-1 
 During the early phase of the infection, the immune system remains 
capable of mounting a response against HIV-1; however, the cell-mediated and 
humoral responses elicited by the infection are limited. CD8+ T cells undergo 
expansion to directly target infected cells during the acute phase of infection. 
Though capable of removing infected cells, the CD8+ T cells’ destruction of 
infected cells may exacerbate the depletion of CD4+ T cells in the system 
(aidsinfo.nih.gov, 2016).  
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 The immune system cannot effectively mount a response against the 
infection because of the inaccurate transcription of the viral genetic material by 
HIV-1 reverse transcriptase (Abbas et al., 2016). As a result, reverse 
transcriptase introduces mutations that may result in a viral product that fails to 
be recognized by the immune system. Consequently, escape mutants emerge 
with new epitopes that are not recognized by the original T cells and may 
eventually overwhelm the immune system (Ananworanich et al., 2016). 
 Several weeks following the initial infection, the immune system is able to 
mount a humoral response against HIV-1 (Abbas et al., 2016). However, these 
early antibodies poorly control the infection due to their weak neutralizing 
properties. The antibodies recognize many different particles of HIV-1; for 
example, a number of antibodies target the Env glycoprotein – particularly gp120 
and gp41 (Ward & Wilson, 2017). Other antibodies recognize and target key viral 
enzymes that function in the maturation of the virus. Regardless, the generation 
of neutralizing antibodies cannot match the mutability of HIV-1. 
 If left untreated, most infected individuals gradually develop AIDS; 
however, the rate of progression distinguishes infected individuals from one 
another. Infections are classified as a rapid progression if AIDS develops within 
three years of acquisition. If an infected person develops AIDS within three to ten 
years, the person is deemed as an intermediate progressor. Lastly, an 
approximated 5% of infected individuals are referred to as long-term non-
progressors (LTNPs) and clinically present with 5000 copies of HIV-1 RNA per 
 8 
milliliter of blood (Kumar, 2013). Furthermore, a subset of LTNPs are termed 
“elite controllers” if they clinically present with viral loads below 50 copies of HIV-
1 RNA per milliliter of blood (Saag & Deeks, 2010). Despite the variances in 
progression, early detection remains invaluable in determining the proper 
treatments to manage the infection.  
 
Treatments 
 Presently, antiretroviral therapies (ART) control infection through a 
combination of drugs that target different aspects of the HIV-1 life cycle. For 
example, nucleoside analogues inhibit reverse transcriptase thereby hindering 
reverse transcription of the viral genetic material into viral DNA. Integrase 
inhibitors prevent the integration of the HIV-1 DNA transcript produced by 
reverse transcriptase. To ensure propagation, the virus requires assembly in 
order to infect other cells; some drugs administered through ART specifically 
block enzymes necessary for the assembly and maturation of HIV-1 (Abbas et 
al., 2016). Targeting different parts of the viral life cycles proves to be effective; 
however, HIV-1 remains capable of developing resistances to antiretroviral 
therapies. While ART medications prove effective in controlling viral replication, 
they do not completely eradicate the infection. The virus coevolves with the 
immune system and may eventually become resistant thereby leading to the 
generation of escape mutants. However, a promising countermeasure against 
the virus lies in the development of broadly neutralizing antibodies (bNAbs).  
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 bNAbs desirability as an HIV-1 treatment relies on their ability to inhibit the 
functionality of the Env glycoprotein rendering it unable to bind and infect cells 
expressing CD4 while being highly tolerated by the host. Successful infection 
involves Env-CD4 binding; thus, all subtypes of HIV-1 express Env. Despite 
variances in the genetic sequences among HIV-1 subtypes, env remains highly 
conserved (Stephenson, 2016). Evasion of the immune system requires HIV-1 to 
mutate epitopes recognized by the host; however, drastic changes to important 
genes may be more deleterious to the virus rather than beneficial. For example, 
hypermutation of env may lead to a non-functional CD4 binding site (CD4bs) and 
hinder the ability of HIV-1 to bind and infect CD4 expressing cells. Consequently, 
env sequences continue to be relatively unaltered and recognized by the immune 
system thereby making them excellent targets for therapeutics. 
 Immune recognition by bNAbs proves to be relatively successful at 
neutralizing HIV-1; however, achieving complete inactivity remains difficult due to 
HIV-1’s mutability. bNAbs mainly target the Env glycoprotein, but several factors 
hinder their functionality. B cell activation requires cross-linking with other cells; 
however, the wide spatial arrangement of Env trimers makes B cell activation 
limited (Stephenson, 2016). Additionally, the glycosylation of amino acids that 
compose Env trimers present themselves as an obstacle for bNab efficacy 
(Stephenson, 2016). The glycosylated amino acids resemble naturally-occuring 
amino acids and mask Env thereby making the glycoprotein weakly immunogenic 
(Stephenson, 2016). Lastly, the quaternary structure of Env generally makes the 
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highly conserved regions inaccessible (Stephenson, 2016). The first variable loop 
(V1) and second variable loop (V2) regions of Env are prone to mutation and 
vary in length and glycosylation, thereby conferring protection of the CD4bs by 
obstructing possible neutralizing antibodies (Stephenson, 2016). Despite the 
limitations of bNAbs, they exhibit a promising aspect in terms of therapeutics and 
help guide the design of vaccines against HIV-1. 
 Developing an effective vaccine continues to be a challenge. Presently, 
four vaccine techniques have been clinically studied for their efficacy. In 2003, 
the AIDSVAX Env gp120 protein vaccine was tested, but proved to not be 
effective in the phase 3 studies that were conducted in the United States and 
Thailand (Flynn et al., 2005; Pitisuttithum et al., 2006). The second vaccine 
platform evaluated an adenovirus serotype 5 (Ad5) vector that expressed Gag, 
Pol, and Nef (Buchbinder et al., 2008). This vaccine also showed no protection 
and produced an undesirable effect of potentially increasing HIV-1 acquisition 
(Barouch, 2013). The third vaccine concept studied was the administration of a 
canarypox ALVAC vector followed by the AIDSVAX Env gp120 (Rerks-Ngarm et 
al., 2009). The results showed a 31.2% decrease in acquiring an HIV-1 infection 
due to the vaccine-elicited antibodies targeting Env V1 and V2 regions. The final 
HIV-1 vaccine clinical trial was another prime-boost study that involved a DNA 
vaccine developed by the National Institutes of Health (NIH) Vaccine Research 
Center followed with a boost using Ad5 vectors that expressed Env, Gag, and 
Pol (Hammer et al., 2013). Unlike the second clinical trial, there was no evidence 
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of increased acquisition through the use of the Ad5 vector. Additionally, the 
regimen resulted in inducing the humoral and cell-mediated immune responses. 
However, the levels of neutralizing and V2-specific antibodies were low and the 
study was halted due to limited success (Barouch, 2013). Despite the difficulties 
encountered, there is evidence that it is likely that a vaccine can be developed to 
generate high-affinity broadly neutralizing antibodies against HIV-1. Although a 
wide variety of therapies have been developed, an effective vaccine remains as 
the most promising solution to eradicating the global HIV-1 epidemic (Barouch, 
2008). 
  
Simian-Human Immunodeficiency Virus (SHIV) 
 The mutability of HIV-1 presents a difficult challenge regarding the 
development of effective treatments and vaccines. Due to ethical reasons, 
humans cannot be purposefully infected with HIV-1 for studies; thus, rhesus 
macaques serve as a model organism for studies regarding the efficacy of 
antiviral therapeutics. However, HIV-1 poorly infects rhesus macaques. To 
circumvent this issue, studies utilize the simian-human immunodeficiency virus 
(SHIV) – which is a chimera of an SIV backbone with a human envelope.  
Most SHIVs utilized for studies contain env sequences from individuals 
infected with clade B of HIV-1. As evidenced by Figure 3, clade B is 
predominantly found in the Western Hemisphere; however, the majority of 
individuals infected with HIV-1 live in the developing world. To represent those 
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regions, SHIVs containing env from clades AE and C, which are primarily found 
in Africa and Southeast Asia respectively, have been developed (Chang et al., 
2015; Tartaglia et al., 2016). 
 
 
Figure 3. Global Distribution of HIV-1 Subtypes and Recombinants. Majority 
of SHIVs to date contain env sequences from HIV-1 clades in the Western world. 
(http://www.microbiologybook.org/lecture/hiv6.htm). 
  
  The use of SHIVs have greatly improved the study of anti-HIV-1 
therapeutics and vaccine development. Many of the SHIV strains used for 
evaluation were originally derived from SHIVHXBc2 generated by introducing 
HIV-1 HXBc2 tat, rev, and env sequences into SIVmac239 as evidenced by 
Figure 4 (Li et al., 2016). Eventually, the HXBc2 env was replaced with the env 
sequence of HIV-1 89.6, which expresses CCR5/CXCR4 tropism (Li et al., 2016). 
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Further changes were introduced through in vivo passaging in RMs, which 
ultimately led to the generation of a CXCR4 tropic virus referred to as SHIVKB9-
AC. This strain of SHIV is preferred for evaluating the efficacy of different HIV-1 
treatments (Li et al., 2016). 
 Despite their contributions to the field, SHIVs developed with the KB9-AC 
backbone possess several flaws; particularly, the KB9-AC backbone contains 
four mutations that negatively affect SHIV infectivity (Li et al., 2016). However, Li 
et al. (2016) have shown that designing SHIVs within the SHIV.C.CH505.dct 
backbone enhances pathogenicity and viral entry. A difference between the two 
backbones results from the original SIV backbone used for SHIV design. The 
KB9-AC backbone is derived from SIVmac239 whereas the SHIV.C.CH505.dct 
backbone stems from SIVmac251. Additionally, the Env glycoprotein expressed 
by viruses with the SHIV.C.CH505.dct backbone possess an extended gp41 tail 
that arose from mutations, but was kept because the tail conferred enhanced 
viral entry (Li et al., 2016). 
Most SHIVs are only utilized for acquisition studies since the HIV-1 Env 
glycoprotein binds inefficiently to RhCD4. However, the affinity for RhCD4 could 
potentially be enhanced by replacing the naturally-occuring amino acid at 
position 375 of Env with a hydrophobic or a basic amino acid, as was shown by 
Li et al (2016). Position 375 is critical because it belongs to the CD4-binding 
pocket of Env and directly interacts with the phenylalanine in position 43 (43F) of 
rhesusCD4; thus, the resulting amino acid change brings position 375 nearer to 
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43F and may confer increased binding interactions to facilitate viral entry (Figure 
5). Development of novel SHIVs will aid in creating animal models that 
recapitulate chronic infection and AIDS progression in humans. 
  
1
5 
 
Figure 4. SHIV Backbone and HIV-1 env. SHIVs contains env sequences from acutely-infected individuals. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Position 375 of Env and Position 43 of RhesusCD4. The change in the amino acids may confer 
increased affinity of Env for rhesusCD4 and facilitate binding. 
43F 43F 43F WT 
375S
375H 375M 
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MATERIALS AND METHODS 
 
Design and Construction of SHIVs 
 Six constructs of SHIV162p3 (WT, M, H, W, Y, F) and six constructs of 
SHIVAE16 (WT, M, S, W, Y, F) were designed with env sequences from acutely-
infected individuals. Clades B and AE env sequences were purchased from 
GeneArt (Thermo Fisher Scientific, Waltham, MA) and mutations were introduced 
via site-directed mutagenesis (New England Biolabs, Ipswich, MA) in order to 
induce a corresponding amino acid change within position 375 (Table 1).  
 Following mutagenesis, the env sequences were cloned into the 
SHIV.C.CH505.dct backbone provided by Dr. George M. Shaw (University of 
Pennsylvania, Philadelphia, PA) using the restriction enzymes MFEI and AVRII. 
Once the plasmids were cloned, we refer to the modified SHIVs as “optimized.”
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Table 1. Site-directed Mutagenesis Primer Sequences 
Primer Name Primer Sequencea 
SHIV162p3.His.Fwd TGTAATGCACCATTTTAATTGTGGAGGGGAATTTTTC  
SHIV162p3.Met.Fwd TGTAATGCACATGTTTAATTGTGGAGGGGAATTTTTC  
SHIV162p3.Tyr.Fwd TGTAATGCACTATTTTAATTGTGGAGGGGAATTTTTC  
SHIV162p3.Trp.Fwd TGTAATGCACTGGTTTAATTGTGGAGG  
SHIV162p3.Phe.Fwd TGTAATGCACTTTTTTAATTGTGGAGGGGAATTTTTC  
SHIV162p3.Uni.Rev ATTTCTGGGTCCCCTCCTG  
SHIVAE16.Ser.Fwd TACAACGCATAGTTTTAATTGTAGAGGG  
SHIVAE16.Met.Fwd TACAACGCATATGTTTAATTGTAGAGGGGAATTTTTC  
SHIVAE16.Tyr.Fwd TACAACGCATTATTTTAATTGTAGAG  
SHIVAE16.Trp.Fwd TACAACGCATTGGTTTAATTGTAGAGGGG  
SHIVAE16.Phe.Fwd TACAACGCATTTTTTTAATTGTAGAGGG  
SHIVAE16.Uni.Rev ATTTCTAGATCTCCTCCTG  
 
 
Sanger Sequencing of Optimized SHIVs 
 Sanger sequencing was performed on all optimized SHIVs. All clones 
were analyzed using select primers (Tables 2 and 3). Comparison of the 
optimized sequences relative to the reference sequence revealed if the desired 
mutation was introduced in the env sequence inserted into the SHIV backbone. 
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Table 2. Sequencing Primers for SHIV162p3  
Primer Name Primer Sequence 
SHIV162p3.optimized.seq.fwd.1 GCATGCTATAAATGGAGC 
SHIV162p3.optimized.seq.fwd.2 TAGTTGTGTGGACCATAG 
SHIV162p3.optimized.seq.fwd.3 AATGTCTGGGCCACACAT 
SHIV162p3.optimized.seq.fwd.4 AGATGCAGAAAGAATATG 
SHIV162p3.optimized.seq.fwd.5 GAAGGGGTAGTAATTAGA 
SHIV162p3.optimized.seq.fwd.6 GAAATTGTAATGCACAGT 
SHIV162p3.optimized.seq.fwd.7 ATGAGGGACAATTGGAGA 
SHIV162p3.optimized.seq.fwd.8 AAGAGTCCTGGCTGTGGA 
SHIV162p3.optimized.seq.fwd.9 ATATCAAAATGGCTGTGG 
SHIV162p3.optimized.seq.fwd.10 ATCTTAATTGCAGCGAGG 
SHIV162p3.optimized.seq.fwd.11 GGCTTGAGCTCACTCTCT 
SHIV162p3.optimized.seq.rev.1 CTCGTGGCATCACTGGTA 
SHIV162p3.optimized.seq.rev.2 AAATAGCTCCACCCATAT 
SHIV162p3.optimized.seq.rev.3 TTCGGGCCTGGCGGGTCC 
SHIV162p3.optimized.seq.rev.4 CCACTCCATCCAGGTCAT 
SHIV162p3.optimized.seq.rev.5 CCCATAGTGCTTCCTGCT 
SHIV162p3.optimized.seq.rev.6 GCTTTTCCTACTTCCTGC 
SHIV162p3.optimized.seq.rev.7 TATCTCCTATTATGTCTC 
SHIV162p3.optimized.seq.rev.8 CAGCCGGGGCACAATAAT 
SHIV162p3.optimized.seq.rev.9 GGGGTTAACTTTACACAT 
SHIV162p3.optimized.seq.rev.10 ATCCCAAGGAGCAAGGTG 
SHIV162p3.optimized.seq.rev.11 CTGTCTCCGCTTCTTCCT 
a
Melting temperatures were 63°C.
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Table 3. Sequencing Primers for SHIVAE16  
Primer Name Primer Sequence 
SHIVAE16.optimized.seq.fwd.1 GCATGCTATAAATGGAGC 
SHIVAE16.optimized.seq.fwd.2 TAGTAGTGTGGACTATAG 
SHIVAE16.optimized.seq.fwd.3 AATGTCTGGGCCACACAT 
SHIVAE16.optimized.seq.fwd.4 AGAGATAGGAAGCAGAAG 
SHIVAE16.optimized.seq.fwd.5 CTAGCAGAAGGGAAGATA 
SHIVAE16.optimized.seq.fwd.6 GGAGATCTAGAAATTACA 
SHIVAE16.optimized.seq.fwd.7 TATAAAGGACAATTGGAG 
SHIVAE16.optimized.seq.fwd.8 ATTAAACAGCTCCAGGCG 
SHIVAE16.optimized.seq.fwd.9 TTTGACATAACAAGTTGG 
SHIVAE16.optimized.seq.fwd.10 CTTAATCTTAATTGCAGC 
SHIVAE16.optimized.seq.fwd.11 AGACAAGGGCTTGAGCTC 
SHIVAE16.optimized.seq.rev.1 CTCGTGGCATCACTGGTA 
SHIVAE16.optimized.seq.rev.2 AAATAGCTCCACCCATAT 
SHIVAE16.optimized.seq.rev.3 TTCGGGCCTGGCGGGTCC 
SHIVAE16.optimized.seq.rev.4 TCCCATTGTGTCCATGTC 
SHIVAE16.optimized.seq.rev.5 CCCATAGTGCTTCCTGCT 
SHIVAE16.optimized.seq.rev.6 ATTGCTTGTCCTGCTCCC 
SHIVAE16.optimized.seq.rev.7 TCTCCTGTTATTTCCCCC 
SHIVAE16.optimized.seq.rev.8 CAGCTGGAGTACAATAAT 
SHIVAE16.optimized.seq.rev.9 CATAGAGGAGTTAACTTT 
SHIVAE16.optimized.seq.rev.10 ATTACCAACCCAAGGATC 
SHIVAE16.optimized.seq.rev.11 TCGCTGTCTCCGCTTCTT 
a
Melting temperatures were 58°C.
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Verification of env Sequence Insertion into the SHIV Backbone via Agarose 
Gel Electrophoresis 
 Restriction digestion was conducted to verify the presence of the mutated 
env sequence within the viral backbone using the restriction enzymes MFEI and 
AVRII. Restriction-digested DNA samples were analyzed by agarose gel 
electrophoresis. 
 
Generation of Small-scale SHIV Stocks 
 Human Embryonic Kidney cells (293T) were cultured in 15 cm plates with 
Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher, Waltham, MA) 
supplemented with 10% fetal bovine serum. 293T cells were seeded at a 
concentration of 5.0 x 106 at least 24 hours in advance to reach an optimal cell 
density of 90% prior to transfections.  
 After a 24-hour incubation period (37° C, 10% CO2), the original media 
was aspirated and replaced with 10 ml of supplemented media and allowed to 
incubate for one hour. Subsequently, 293T cells were transfected with the 
optimized SHIVs using a mixture of LipoD293 transfection reagent (SignaGen 
Laboratories, Rockville, MD) and serum-free media at a concentration of 30 
µg/ml and were incubated for an additional 72 hours according to the 
manufacturer’s protocol. After 72 hours of incubation, transfected 293T cells 
were harvested and viral supernatants were collected and stored at 4° C. 
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 Human and rhesus peripheral blood mononuclear cells (PBMC) were 
isolated from whole blood by Ficoll-Hypaque gradient purification and stimulated 
with concanavalin A (Con A; 6.25 µg/ml) and human interleukin-2 (IL-2; 20 
units/ml; AIDS Research and Reference Reagent Program, Germantown, MD) 
overnight. Human and rhesus PBMCs were purchased commercially (Research 
Blood Components, Brighton, MA; AlphaGenesis, Yemassee, SC). Cells were 
cultured in RPMI 1640 medium supplemented with 20% fetal bovine serum, 100 
units/ml penicillin, 100 µg/ml streptomycin, and 20 units/ml of IL-2. Once 
stimulated, human and rhesus PBMCs were incubated for a period of 72 hours 
prior to infection. 
 After 72 hours, the human and rhesus PBMCs were harvested and 
centrifuged for 5 minutes at 1700 revolutions per minute (RPM) in a Thermo 
Fisher Sorvall Legend XTR centrifuge. The media was aspirated and replaced 
with 5 ml of viral supernatant and resuspended. The human and rhesus PBMCs 
were incubated at room temperature for one hour to allow for viral attachment 
and entry in cells. Following incubation, human and rhesus PBMCs were 
transferred to T75 flasks and an additional 15 ml of the supplemented RPMI 
1640 media was added for a total volume of 20 ml per flask. The cells were 
incubated at 37° C for 72 hours. 
 After 72 hours, the human and rhesus PBMCs were harvested and 
transferred to 50 ml conical tubes and centrifuged for 5 minutes at 1700 RPM. 
The supernatant was aspirated and replaced with 20 ml of supplemented RPMI 
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1640 media. The cycle was repeated every 3 days with the viral supernatants 
collected at 3-day increments beginning from Day 6. The samples were then 
analyzed by SIV p27 enzyme-linked immunosorbent assay (ELISA; Zeptometrix, 
Franklin, MA).  
 
Quantification of Viral Supernatants by SIV p27 ELISA and qPCR 
 Harvested viral supernatants were analyzed by SIV p27 ELISA according 
to the manufacturer’s instructions. 450 µl of each SHIV was treated with 50 µl of 
lysing buffer. Additionally, microplate wells were washed with 200 µl of 1X plate 
wash buffer, aspirated, and dried on absorbent towels. This step was repeated 
six more times. Following the wash, 200 µl of lysed sample was placed into each 
well. Once all samples were transferred into the wells, the microplate was 
covered and incubated at 37° C for 2 hours. After incubation, the plates were 
aspirated and washed with 200 µl of the 1X plate wash buffer and repeated for a 
total of six times. After the wash, 100 µl of SIV p27 detector antibody was 
pipetted into each well and incubated at 37° C for one hour. After the incubation 
period, the plate was aspirated and washed with 1X plate wash buffer and dried 
six times. 100 µl of substrate working solution was then added to each well and 
incubated for 30 minutes at room temperature. The reaction was stopped with 
100 µl of stop solution. Within 15 minutes, the plates were ready to be analyzed 
at an optical wavelength of 450 nm using a microplate reader. 
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TCID50 Titer in TZM.bl Cells 
 SHIV infectivity was quantified by inoculating TZM.bl cells in order to 
determine the lowest concentration necessary to infect 50% of TZM.bl cells. 
Virus stocks were serially diluted with 11 µg/ml of DEAE-dextran hydrochloride 
(Sigma, St. Louis, MO) in quadruplicate wells. SHIV infectivity was determined 48 
hours following infection by measuring levels of luciferase activity expressed by 
infected cells. TCID50 values were determined with the help of Dr. Michael 
Seaman (Center for Virology and Vaccine Research, Boston, MA).  
 
Animals 
 Rhesus macaques  (Macaca mulatta) of Indian origin were challenged 
with viruses. Sixteen Mamu-A*01-negative adult male and female animals were 
housed at Bioqual (Rockville, MD).  
 
Ethics 
  All animals were maintained in accordance with the Association for 
Assessment and Accreditation of Laboratory Animals with the appropriate 
approvals from the relevant Institutional Animal Care and Use Committees 
(IACUC). The Harvard Medical School Standing Committee on Animals (#03970) 
and the Bioqual IACUC approved these studies. The animal protocols adhered to 
NIH standards set forth in the “Policy on Humane Care of Vertebrate Animals 
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Used in Testing, Research, and Training” and the “Guidelines for the Care and 
Use of Laboratory Animals” (DHHS publication #NIH 85-23).  
 Animal welfare was maintained by the Bioqual animal management 
programs, which are accredited by the American Association for the 
Accreditation of Laboratory Animal Care (AAALAC) and meet all applicable 
federal and institutional standards for housing, monkey diet, water ad libitum, 
social enrichments, and steps intended to minimize suffering, such as the use of 
anesthesia for study procedures and analgesia for invasive procedures like 
biopsies.  
 
Intravenous Inoculation of SHIVs 
 The sixteen animals were divided into four groups with each group 
consisting of four RMs. Each animal in all groups received a single intravenous 
(IV) challenge with 1 ml of virus (Table 4). Group 1 RMs received 1 ml of the 
original SHIV162p3 challenge stock at a concentration of 1.0 x 108 RNA 
copies/ml. Group 2 animals were challenged with 1 ml of a mixture of the 
modified SHIV162p3 wild-type and mutant viruses at a 1:1 measuring at a 
concentration of 1.0 x 108 RNA copies/ml of each virus.  Group 3 animals 
received 1 ml of the original SHIVAE16 challenge stock at a concentration of 1.0 
x 108 RNA copies/ml. Group 4 RMs were challenged with 1 ml of a mixture of the 
modified SHIVAE16 wild-type and mutant viruses at a 1:1 measuring at a 
concentration of 1.0 x 108 RNA copies/ml for each virus.
  
2
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Table 4. SHIV Pool Infection Study Dilution Schema     
Monkey ID #a SHIVb 
Viral Load   
(RNA copies/ml) 
(RNA copies/ml)/ 
1.0 x 108 = X (µl) 
(1 ml)/X 
= (µl) 
Final Volume 
per Monkey (µl) 
Diluent 
(µl)c 
Group 1       
T547, T549, T550, T571 
162p3 
Original 3.48x 108 3.48 287.36 287 713 
Group 2       
T551, T552, T553, T554 162p3 WT 1.07 x 109 10.71 93.41 93 907 
 
162p3 M 6.24 x 108 6.24 160.28 160 840 
162p3 H 1.00 x 109 10.02 99.82 100 900 
162p3 W 5.89 x 108 5.89 169.92 170 830 
162p3 Y 7.33 x 108 7.33 136.43 136 864 
162p3 F 8.53 x 108 8.53 117.23 117 883 
Group 3       
T556, T557, T558, T559 
AE16 
Original 2.10 x 109 21.00 47.62 48 952 
Group 4       
T566, T567, T568, T569 AE16 WT 6.13 x 109 61.30 16.31 16 984 
 AE16 M 9.43 x 108 9.43 106.07 106 894 
 AE16 S 1.76 x 109 17.60 56.83 57 943 
 AE16 W 6.97 x 108 6.97 143.43 143 857 
 AE16 Y 2.84 x 109 28.42 35.18 35 965 
 AE16 F 8.33 x 108 8.33 120.05 120 880 
a
T corresponds to the monkey ID number; 
b
Groups 1 and 3 are original SHIV stocks cloned in the KB9-AC backbone, while groups 2 and 
4 are modified SHIV stocks cloned in the SHIV.C.CH505.dct backbone;
 c
Serum-free RPMI used as diluent.
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Post-challenge Schema 
 The study schedule for the collection of serum, lymph nodes, and 
colorectal biopsies and post-processing analyses are shown in Table 5. 
 
Table 5. SHIV Pool Infection Study Schedule   
Week Day Procedurea Date EDTAb    (ml) Serumc (ml) Bxd 
0 0 SHIV IV 2/21/2017 10 5 N/A 
1 7 SHIV IV 2/28/2017 10 5 N/A 
2 14 SHIV IV 3/7/2017 10 5 N/A 
4 28 SHIV IV 3/21/2017 20 5 CR/LN 
8 56 SHIV IV 4/18/2017 10 5 N/A 
12 84 SHIV IV 5/16/2017 10 5 N/A 
16 112 SHIV IV 6/13/2017 10 5 N/A 
a
All animals were challenged intravenously with SHIV stocks according to schema in Table 1; 
b
CBC, CD3/4/8, freeze plasma for viral loads and sequencing, freeze PBMC for cellular assays; 
c
Freeze for antibody assays; 
d
Freeze for viral loads and pathology. 
 
 
CD4+ T Cell Counts 
EDTA-anticoagulated whole blood, PBMC, and lymph node mononuclear 
cells (LNMCs) were stained using anti-CD3+-allophycocyanin (APC), anti-CD4+-
phycoerythrin (PE), and anti-CD8+-fluorescein isothiocyanate (FITC) monoclonal 
antibodies (mAbs) and analyzed using a FACSCalibur flow cytometer (BD 
Biosciences, San Jose, CA). Cell counts were determined using the BD True 
Count tubes according to the manufacturer’s instructions (BD Biosciences). 
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RESULTS 
 
Generation of Clades B and AE SHIV Small-scale Stocks 
 All six constructs of clade B (SHIV162p3 WT, M, H, W, Y, F) and all six 
constructs of clade AE (SHIVAE16 WT, M, S, W, Y, F) were cloned into the 
SHIV.C.CH505.dct backbone. Restriction digestions were performed on all 
optimized SHIV plasmids to ensure successful cloning. A theoretic digest 
indicates that a digestion by MFEI and AVRII yields two bands, a 12 kb fragment 
that corresponds to the SHIV.C.CH505.dct backbone and a 3 kb fragment for the 
mutated env. Agarose gel electrophoresis resulted in the presence of fragments 
of the correct sizes (Figure 6). 
 Assembled constructs were then sequenced to determine the presence of 
the desired substitutions at amino acid position 375. The parental sequence was 
used as a reference for comparison to the modified SHIVs. All six SHIV162p3 
constructs and all six SHIVAE16 constructs presented the corresponding 
nucleotide changes that confer the desired amino acid substitution as evidenced 
by Figure 7-A and Figure 7-B.
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Figure 6. Verification of Assembled Plasmids by Restriction Enzyme (RE) 
Digestion. C1 – C4 are four plasmids that were screened by RE digestion and 
compared to a marker (M) that revealed the presence of a 12 kb SHIV backbone 
fragment and 3 kb env fragment. 
 
C1 C2 C3 C4  M 
12 kb 
3 kb 
2 kb 
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Figure 7-A. Sanger Sequencing Results for SHIV162p3 Plasmids. Red 
nucleotides confer amino acid substitutions at position 375 of Env. Comparison 
of the SHIV sequences to the reference sequence indicates that the desired 
substitutions were successfully introduced in the env sequence. 
 
  
 
Figure 7-B. Sanger Sequencing Results for SHIVAE16 Plasmids. Red 
nucleotides confer amino acid substitutions at position 375 of Env. Comparison 
of the SHIV sequences to the reference sequence indicates that the desired 
substitutions were successfully introduced in the env sequence. 
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Viral Loads of clade B and AE SHIVs Small-scale Stocks 
Viral load analyses were conducted to determine the concentration of 
RNA copies present in PBMC supernatants. Concentrations for SHIV162p3 WT 
and mutants ranged from 5.89 x 108 to 1.07 x 109 viral proteins per milliliter 
(vp/ml), while SHIVAE16 concentrations ranged between 6.97 x 108 to 6.13 x 109 
vp/ml. SHIV325c was used as a positive control for this assay (Table 6).
 
Quantification of Viral Supernatants by SIV p27 ELISA  
 Viral replication and growth in PBMC supernatants were quantified by SIV 
p27 ELISA. Harvested PBMC supernatants from all time points were compared 
to control virus, SHIV325c. Color intensities were analyzed by a microplate 
reader at an optical wavelength of 450 nm, which indicated the presence and 
concentrations of viral particles. PBMC p27 values for the modified SHIV162p3 
WT and mutants ranged from 18.82 to 37.63 nanograms per millililter (ng/ml). 
The modified SHIVAE16 WT and mutants ranged from 30.25 to 362.20 ng/ml. 
 
SHIV Infectious Dose by TCID50 Assay 
 TCID50 assays were conducted to determine the concentration of virus 
necessary to infect at least 50% of cells. TCID50 values for modified SHIV162p3 
WT and mutants ranged from 1.83 x 104 to 1.67 x 10
8 TCID/ml. TCID50 
concentrations for SHIVAE16 WT and mutants ranged from 1.00 x 104 to 1.95 x 
107 TCID50/ml (Table 6). 
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Table 6. Summary of Small-scale SHIV Challenge Stocks  
SHIV PBMCa 
Days 
Pooledb 
Viral Load         
(RNA copies/ml)c 
PBMC 
p27 
(ng/ml)d 
Infectivity 
Titer 
(TCID50/ml)e 
162p3      
Original Rhesus N/A 3.48 x 108 14.51 1.75 x 106 
WT Rhesus 6, 10 1.07 x 109 35.65 1.67 x 108 
M Rhesus 6, 10, 12 6.24 x 108 23.05 1.95 x 107 
H Rhesus 6, 10, 12 1.00 x 109 22.18 1.95 x 107 
W Rhesus 6, 10 5.89 x 108 18.82 1.83 x 104 
Y Rhesus 10, 13, 16 7.33 x 108 20.01 7.81 x 105 
F Rhesus 10, 13 8.53 x 108 37.63 3.91 x 106 
AE16      
Original Human N/A 2.10 x 109 102.90 1.00 x 104 
WT Human 10, 13 6.13 x 109 362.20 1.95 x 107 
M Human 21, 24 9.43 x 108 32.70 3.49 x 105 
S Human 21, 24 1.76 x 109 45.10 3.13 x 104 
W Human 21, 24 6.97 x 108 36.80 4.57 x 105 
Y Human 6, 10, 12, 15 2.84 x 109 114.95 3.91 x 106 
F Human 18, 21 8.33 x 108 30.25 1.75 x 106 
a
PBMC utilized for SHIV generation; 
b
days pooled post-infection and frozen at -80°C; 
c
viral load 
(RNA copies/ml); 
d
SIV p27 levels in PBMC; 
e
infectivity in TZM.bl cells (TCID50/ml). 
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Intravenous Inoculation of Modified SHIV162p3 and SHIVAE16 in Rhesus 
Macaques 
 The ability of the modified SHIV162p3 and SHIVAE16 to infect rhesus 
macaques in vivo by the IV route was assessed, as well as to determine which of 
the modified SHIVs were the most infectious. Additionally, the pathogenicity of 
the modified SHIVs was compared relative to the infectivity of the original 
challenge stocks. Sixteen adult RMs were challenged and all animals exhibited 
peak viral loads at week 2 post challenge. Group 1 animals were challenged with 
the original SHIV162p3 challenge stock and viral loads ranged from 8.66 x 106 to 
4.98 x 107 RNA copies/ml (Figure 8-A), while CD4+ T cell declines ranged from 
16.50 to 20.10% (Figure 8-B). Group 2 animals were challenged with a 1:1 
mixture of the modified SHIV162p3 and presented with viral loads ranging from 
7.26 x 106 to 1.17 x 108 RNA copies/ml (Figure 8-A), whereas CD4+ T cell 
declines ranged from 15.60 to 22.70% (Figure 8-B).  
 Group 3 animals were challenged with the original SHIVAE16 stock. The 
infected animals exhibited peak viral loads ranging from 1.17 x 105 to 2.06 X 107 
RNA copies/ml (Figure 9-A), while CD4+ T cell declines ranged from 7.70 to 
28.40% (Figure 9-B). As for Group 4, which were infected with a 1:1 mixture of 
the modified SHIVAE16, peak viral load values ranged from 3.02 x 106 to 1.75 x 
107 RNA copies/ml (Figure 9-A), whereas CD4+ T cell declines ranged from 11.90 
to 21.00% (Figure 9-B). 
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Figure 8-A. SHIV162p3 Original vs Modified Pool Viral Loads. Black lines 
represent RMs infected with original SHIV162p3. Red lines represent RMs 
infected with a pool of the modified SHIV162p3. Dotted line represents limit of 
detection (LOD). Peak viral loads presented two weeks post challenge. 
 
 
 
Figure 8-B. SHIV162p3 Original vs Modified Pool CD4+ T Cell Counts. Black 
lines represent RMs infected with original SHIV162p3. Red lines represent RMs 
infected with modified SHIV162p3 pool. CD4+ T cell counts are presented as 
percentages. 
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Figure 9-A. SHIVAE16 Original vs Modified Pool Viral Loads. Blue lines 
represent RMs infected with original SHIVAE16. Green lines represent RMs 
infected with the modified SHIVAE16 pool. Dotted line represents LOD. Peak 
viral loads presented two weeks post challenge. 
 
 
 
 
Figure 9-B. SHIVAE16 Original vs Modified Pool CD4+ T Cell Counts. Blue 
lines represent RMs infected with original SHIVAE16. Green lines represent RMs 
infected with modified SHIVAE16 pool. CD4+ T cell counts are presented as 
percentages. 
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DISCUSSION 
 
 SHIVs play a determining role in the development of an animal model that 
recapitulates the prominent features of HIV-1 infection in humans. The goal of 
this project was to develop novel SHIVs that were highly pathogenic and would 
improve upon the animal models currently used for assessing the efficacy of 
curative and preventative therapeutics aimed at targeting HIV-1. 
 Design of novel SHIVs began with the insertion of mutated env sequences 
from acutely-infected individuals into the SHIV.C.CH505.dct provided by Dr. 
George Shaw (University of Pennsylvania, Philadelphia, PA). The mutations 
were introduced to substitute the wild-type amino acid in position 375 of the Env 
glycoprotein for bulky hydrophobic and/or basic amino acids. Introducing these 
substitutions shortens the distance between position 375 of HIV-1 Env, which 
directly interacts with a phenylalanine on position 43 of rhCD4 (Li et al., 2016). 
These substitutions may enhance the binding interactions of Env to rhCD4 
thereby increasing the likelihood of viral entry and infection. These novel SHIVs 
were designed to enhance the pathogenicity of our original SHIV162p3 and 
SHIVAE16 challenge stocks.  
 The mutated env sequences for SHIV162p3 and SHIVAE16 were 
successfully cloned into the SHIV.C.CH505.dct backbone and conferred the 
desired amino acid substitutions, as evidenced by the agarose gel 
electrophoresis and sequencing results (Figure 6). Relative to our original 
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challenge stocks, the viral loads of the modified SHIV162p3 challenge stocks 
(WT and mutants) presented in greater RNA copies/ml overall (Table 6). 
Additionally, quantification by ELISA revealed that all novel SHIVs exhibited 
higher concentrations than the original challenge stocks (Table 6). Regarding 
their infectivity, four SHIVs (the modified WT and the M, H, and F mutants) were 
more infectious than the original challenge stocks (Table 6). As for SHIVAE16, 
two SHIVs (the modified WT and Y mutant) displayed higher viral loads and p27 
titers than the original challenge stock (Table 6). However, all SHIVs presented 
with greater infectivity titers than the original SHIVAE16 challenge stock (Table 
6). These SHIV stocks were used to inoculate sixteen RMs, all of which became 
infected as evidence by Figure 8-A and Figure 9-A. 
 The differences in in vitro growth kinetics and pathogenicity between the 
modified SHIV162p3 and SHIVAE16 relative to the original challenge stocks may 
result from several factors. The mutants may be more successful as a result of 
the introduced mutations that conferred amino acid substitutions that facilitated 
Env-rhCD4 binding. As for the modified WT for both SHIV162p3 and SHIVAE16, 
the SHIV.C.CH505.dct backbone possesses several differences compared to the 
original KB9-AC backbone. The SHIV.C.CH505.dct backbone is derived from 
SIVmac251, whereas SHIVKB9-AC stems from SIVmac239. Additionally, 
complete tat-rev-vpu-env cassettes from various HIV-1 strains replaced the SIV 
counterparts for SHIV.C.CH505.dct. Lastly, the Env glycoprotein contains an 
extended gp41 tail that was acquired through mutations and makes the SHIVs 
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more infectious (Li et al., 2016). As for the modified SHIV162p3 and SHIVAE16 
mutants, the increased pathogenicity may be conferred by the inherent properties 
of the SHIV.C.CH505.dct backbone, but also by the amino acid substitutions in 
position 375 of Env. To determine which property augments SHIV pathogenicity, 
the same mutations could be cloned into the original KB9-AC backbone and 
subjected to the same functional analyses.  
 
Future Directions  
The NHP portion of this project is ongoing and several projects will be 
conducted following the 16-week infection study. Following the Week 4 timepoint, 
samples will be continually assessed for viral loads to monitor persistence of 
infection and determine set-point viremia. Additionally, the modified SHIV162p3 
and SHIVAE16 will undergo single genome amplification (SGA) sequencing to 
specifically determine which modified SHIV was the most infectious. 
Subsequently, large-scale challenge stocks of the most infectious virus for both 
SHIV162p3 and SHIVAE16 will be generated and utilized for future studies. 
Neutralization sensitivity of the most infectious virus for SHIV162p3 and 
SHIVAE16 will also be examined with a panel of broadly-reactive mAbs that 
target the major neutralization epitopes to determine potential susceptibility. 
Additionally, the humoral response elicited by the SHIVs will be studied with the 
intent of studying the natural immunological mechanisms in rhesus macaques. 
Potentially, some of the animals infected may mimic the responses of elite 
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controllers living with HIV-1. Assessing the immune response may provide insight 
regarding the rational design for the next generation of mAbs and vaccine 
development. 
  
Conclusions 
Although monumental strides have occurred, eradication of HIV-1 
continues to be challenging as countermeasures are limited to controlling levels 
of infection. Presently, no effective vaccine exists that could prevent infection by 
HIV-1 and its possible progression into AIDS. With continued efforts, a vaccine 
for HIV-1 will be developed; but only with the continued advancement of animal 
models that recapitulate HIV-1 infection in humans. 
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